| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 45.286 | 5.309 | 115.621 | 108.869 | 51.414 | 158.807 | 205.310 | 277.822 | 540.022 |
| Total Income - EUR | 0 | 45.286 | 5.309 | 115.621 | 109.210 | 51.815 | 158.807 | 205.821 | 289.523 | 540.051 |
| Total Expenses - EUR | 0 | 1.551 | 1.593 | 7.771 | 16.503 | 64.222 | 134.590 | 131.299 | 237.589 | 270.218 |
| Gross Profit/Loss - EUR | 0 | 43.736 | 3.716 | 107.850 | 92.707 | -12.408 | 24.217 | 74.523 | 51.934 | 269.833 |
| Net Profit/Loss - EUR | 0 | 42.377 | 3.557 | 104.382 | 89.552 | -13.312 | 22.010 | 72.504 | 49.039 | 240.899 |
| Employees | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
Check the financial reports for the company - Regenage Pharma Laboratoires S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 14.211 | 11.106 | 28.171 | 18.869 | 82.037 | 86.754 |
| Current Assets | 28.596 | 44.455 | 47.425 | 158.311 | 244.128 | 292.782 | 112.945 | 226.683 | 145.823 | 500.118 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 12.929 | 25.053 | 18.194 | 19.227 | 43.951 |
| Receivables | 1.126 | 1.114 | 41.598 | 155.097 | 235.672 | 272.598 | 74.327 | 202.328 | 121.547 | 420.134 |
| Cash | 27.471 | 43.341 | 5.827 | 3.213 | 8.455 | 7.255 | 13.564 | 6.161 | 5.050 | 36.033 |
| Shareholders Funds | 28.446 | 42.476 | 45.314 | 148.865 | 235.534 | 217.756 | 22.119 | 72.614 | 49.148 | 242.727 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 150 | 1.979 | 2.111 | 9.446 | 22.805 | 86.261 | 121.318 | 173.024 | 178.713 | 344.145 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4791 - 4791" | |||||||||
| CAEN Financial Year |
4791
|
|||||||||
Comments - Regenage Pharma Laboratoires S.r.l.